4 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Terminated 1, Unknown 1 |
Follow Biotrial: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function ITF2357 - Hepatic Impairment | Phase 1 | Completed | Italfarmaco | 24 | 2025-05-29 | 2026-06-18 |
| Study to Evaluate LPH-5 in Healthy Subjects LPH-5, Placebo - Safety Issues, Tolerance | Phase 1 | Not yet recruiting | Lophora | 48 | 2025-04-30 | 2024-12-09 |
| Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males VNA-318, Placebo - Healthy Volunteer | Phase 1 | Completed | VANDRIA | 92 | 2024-12-03 | 2025-12-10 |
| Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy Phase 1, SQY51, Phase 2a, SQY51 (cohort 1), Phase 2a, SQY51 (cohort 2) - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Unknown | Sqy Therapeutics | 12 | 2023-04-26 | 2024-04-01 |
| Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours EXS21546 - Advanced Solid Tumours | Phase 1 / Phase 2 | Terminated | Exscientia AI Limited | 6 | 2023-04-11 | 2023-11-08 |
| Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. OMTX705, Pembrolizumab, Tislelizumab (BGB-A317) - Advanced Solid Tumor | Phase 1 | Recruiting | Oncomatryx Biopharma S.L. | 150 | 2022-10-20 | 2025-11-25 |
| Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations Binimetinib 15 MG, Binimetinib 45 MG - Melanoma, BRAF V600 Mutation | Phase 1 | Completed | Pierre Fabre Medicament | 37 | 2022-08-31 | 2024-09-19 |
| Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS Bmab 1000, Prolia® - Healthy Volunteers | Phase 1 | Completed | Biocon Biologics UK Ltd | 190 | 2022-03-09 | 2024-04-17 |
| Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations Binimetinib Oral Tablet - Melanoma, BRAF V600 Mutation | Phase 1 | Unknown | Pierre Fabre Medicament | 14 | 2021-09-03 | 2021-12-01 |
Melanoma (2) · Muscular Dystrophy, Duchenne (1)
binimetinib (2) · Clinical Trials, Phase I as Topic (1) · Denosumab (1) · Patents as Topic (1) · givinostat (1) · givinostat hydrochloride (1) · pembrolizumab (1) · tislelizumab (1)
France (6) · United States (2) · Belgium (1) · Bulgaria (1) · Spain (1)
Marina Klein, MD (2) · Antoine Italiano, MD (1) · Klaus Dugi, MD (1) · Sophie Hays, MD (1)